Pfizer Inc

PFE-N

NYSE:PFE

36.25
0.23 (0.64%)
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City, with its research headquarters in Groton, Connecticut. Pfizer is considered one of the world's largest pharmaceutical companies.
More at Wikipedia

Analysis and Opinions about PFE-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
September 15, 2020
Pfizer is having an analysts day this week. She owns another large pharma (see today's top picks). All the pharmas have said they won't make a lot of money on the vaccine in the first phase at least. They're still building a pipeline of drugs, so she doesn't own it.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 15, 2020
Pfizer is having an analysts day this week. She owns another large pharma (see today's top picks). All the pharmas have said they won't make a lot of money on the vaccine in the first phase at least. They're still building a pipeline of drugs, so she doesn't own it.
DON'T BUY
DON'T BUY
September 14, 2020
It's a bond with drugs. It doesn't have the pipeline of drugs to attract investors.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 14, 2020
It's a bond with drugs. It doesn't have the pipeline of drugs to attract investors.
BUY
BUY
September 4, 2020
One of the largest pharma companies in the world. They have done a good job rebuilding their pipeline of drugs. It's now better built with constant new products. They took a hit due to a cancer drug that didn't prove itself. You get a nice dividend. In the medical space, there are other names like Boston Scientific that could be a good alternative.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
September 4, 2020
One of the largest pharma companies in the world. They have done a good job rebuilding their pipeline of drugs. It's now better built with constant new products. They took a hit due to a cancer drug that didn't prove itself. You get a nice dividend. In the medical space, there are other names like Boston Scientific that could be a good alternative.
SELL
SELL
August 27, 2020

PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
August 27, 2020

PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

PAST TOP PICK
PAST TOP PICK
August 24, 2020
(A Top Pick Sep 16/19, Down 9%) He bought it for stability and the dividend. They have new drugs, including a COVID one. Pays a solid 3.8% dividend. Not worried about this.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
August 24, 2020
(A Top Pick Sep 16/19, Down 9%) He bought it for stability and the dividend. They have new drugs, including a COVID one. Pays a solid 3.8% dividend. Not worried about this.
BUY
BUY
July 21, 2020
Trades at 14x PE and pays almost a 4% dividend. Tailwind is them working on a COVID-19 vaccine, like all its peers. They have a strong backlog of drugs that will come to market. No headwinds politically which is good.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
July 21, 2020
Trades at 14x PE and pays almost a 4% dividend. Tailwind is them working on a COVID-19 vaccine, like all its peers. They have a strong backlog of drugs that will come to market. No headwinds politically which is good.
DON'T BUY
DON'T BUY
July 16, 2020

Went over the patent cliff and is in the process of redeveloping its pipeline. Attractive yield. Owns JNJ instead, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
July 16, 2020

Went over the patent cliff and is in the process of redeveloping its pipeline. Attractive yield. Owns JNJ instead, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.

DON'T BUY
DON'T BUY
July 9, 2020

Main attractions are its cash flow and dividend. Being held back by low earnings growth, low single digits. Instead, look at Abbvie, Merck, or other names with growth but similar valuations.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
July 9, 2020

Main attractions are its cash flow and dividend. Being held back by low earnings growth, low single digits. Instead, look at Abbvie, Merck, or other names with growth but similar valuations.

COMMENT
COMMENT
June 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
June 18, 2020

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

TOP PICK
TOP PICK
May 28, 2020

It is still very cheap in his opinion. It is cheaper than the market multiple. It is growing revenue, earnings and dividends as well as buying back stock. About a 4% dividend yield. A great management team. They merged their consumer business with GSK-N. There should be a boost to the share price when this gets IPOed in two to three years. In the near term there is their generic drug business that is merging with MYL-Q. They will then be an innovation-focused and higher growth R&D kind of Pfizer. (Analysts’ price target is $41.80)

Show full opinionHide full opinion
Pfizer Inc (PFE-N)
May 28, 2020

It is still very cheap in his opinion. It is cheaper than the market multiple. It is growing revenue, earnings and dividends as well as buying back stock. About a 4% dividend yield. A great management team. They merged their consumer business with GSK-N. There should be a boost to the share price when this gets IPOed in two to three years. In the near term there is their generic drug business that is merging with MYL-Q. They will then be an innovation-focused and higher growth R&D kind of Pfizer. (Analysts’ price target is $41.80)

DON'T BUY
DON'T BUY
February 25, 2020
Legislation handcuffs big pharma by letting patents expire and turn to generics. This stops these companies from growing revenue. Big pharma has to keep hitting home runs to survive. When they can't, they cut costs or amalgamate them. He prefers biotechs.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 25, 2020
Legislation handcuffs big pharma by letting patents expire and turn to generics. This stops these companies from growing revenue. Big pharma has to keep hitting home runs to survive. When they can't, they cut costs or amalgamate them. He prefers biotechs.
TOP PICK
TOP PICK
February 11, 2020
They spinning off their low-growth businesses, so the remaining core will be a much higher-growth company. Their will put out an R&D investor update in late March that will be a catalyst for shares to rise. Their but drugs will expire in 2026-7, but their drug pipeline is good enough--they have bench strength. (Analysts’ price target is $43.15)
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 11, 2020
They spinning off their low-growth businesses, so the remaining core will be a much higher-growth company. Their will put out an R&D investor update in late March that will be a catalyst for shares to rise. Their but drugs will expire in 2026-7, but their drug pipeline is good enough--they have bench strength. (Analysts’ price target is $43.15)
HOLD
HOLD
February 6, 2020
Trades at 14-15x earnings. Great dividend, almost 4%. Always pressure to develop drugs in the pipeline. Will have difficulty going into an election. Should do well over the long run.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
February 6, 2020
Trades at 14-15x earnings. Great dividend, almost 4%. Always pressure to develop drugs in the pipeline. Will have difficulty going into an election. Should do well over the long run.
COMMENT
COMMENT
January 30, 2020
The only way they are growing is through massive cost cutting and acquisition. These stocks will all give you dividend growth and decent cash flow. One of their star pain killers is off patent.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 30, 2020
The only way they are growing is through massive cost cutting and acquisition. These stocks will all give you dividend growth and decent cash flow. One of their star pain killers is off patent.
DON'T BUY
DON'T BUY
January 29, 2020
It's performed by cutting costs, not by growth. The reason is that as they develop new drugs, they go off-patent and lose billions. It's a cost story, simply. You're spinning your wheels here.
Show full opinionHide full opinion
Pfizer Inc (PFE-N)
January 29, 2020
It's performed by cutting costs, not by growth. The reason is that as they develop new drugs, they go off-patent and lose billions. It's a cost story, simply. You're spinning your wheels here.
Showing 1 to 15 of 685 entries

Pfizer Inc(PFE-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 7

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 9

Total Signals / Votes : 18

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 18 stock analysts published opinions about PFE-N. 7 analysts recommended to BUY the stock. 9 analysts recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by Christine Poole on 2020-09-15. Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

18 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2020-09-22, Pfizer Inc (PFE-N) stock closed at a price of $36.25.